Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Abstract

Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (Funded by Bristol-Myers Squibb; CheckMate 057 ClinicalTrials.gov number, NCT01673867.).

Keywords

Affiliated Institutions

• Vall d'Hebron Institute of Oncology
• Sarah Cannon US
• Centre Hospitalier Universitaire de Rennes FR
• Breast Cancer Research Foundation US
• University Hospital Heidelberg DE
• Assistance Publique Hôpitaux de Marseille FR
• Aix-Marseille Université FR
• Yale Cancer Center US
• Russian Cancer Research Center NN Blokhin RU
• Sidney Kimmel Comprehensive Cancer Center US
• Istituti di Ricovero e Cura a Carattere Scientifico IT
• Azienda Ospedaliera di Perugia IT
• Instituto Nacional de Cancerología MX
• Centre Léon Bérard FR
• Vanderbilt-Ingram Cancer Center
• Hospital Universitario Virgen del Rocío ES
• University of Chicago US
• Bristol-Myers Squibb (United States) US
• Duke Medical Center US
• Hospital Universitario HM Sanchinarro ES
• Hebron University PS
• Robert Bosch Hospital DE
• Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IT
• Moffitt Cancer Center US
• Fox Chase Cancer Center US
• Tennessee Oncology US
• The University of Texas Southwestern Medical Center US
• University of Washington US
• Memorial Sloan Kettering Cancer Center US
• Seattle University US
• Heidelberg University DE

Related Publications